Leadership
Pierluigi Paracchi

Pierluigi Paracchi
Founder
Chairman and CEO

Former Venture Capitalist: Quantica SGR – Founder and CEO, Axòn Capital – Founder and Investment Manager, Sofinnova Partners – Venture Consultant

>15 years comulated as Investor and Board Directror in Life Sciences companies

Investor and Board Member at EOS – Ethical Oncology Science (acquired by Clovis Oncology, NASDAQ: CLVS)

Independent Member of the Research and Innovation Commission at the Italian Ministry of Health

Member of the Assobiotec Steering Committee, the Italian Association for the development of biotechnology

Member of IAB – Italian Angels for Biotech, national business angel association

Luigi Naldini, Professor

Luigi Naldini, Professor
Founder
Executive Scientific Board Chairman

Director, San Raffaele-Telethon Institute for Gene Therapy (TIGET) & Division of Regenerative Medicine, Stem Cells & Gene Therapy, San Raffaele Scientific Institute

Professor of “Cell and Tissue Biology” and “Cell and Gene Therapy”, “Vita-Salute San Raffaele” University School of Medicine

Past President of the European Society of Gene and Cell Therapy (ESGCT; 2012-2014)

Member of Board of Directors (2005-08) and Advisory Council of the American Society of Gene and Cell Therapy (ASGCT; 2008-12 )

Author of >231 scientific publications, cumulative IF >2.089 (avg. IF 10.93), h-index 78, >27.900 citations

Inventor of 58 granted and 45 pending patents

Scientific Advisor on EMEA and WHO Committees for the evaluation of novel gene transfer medicines

Awarded the European Research Council (ERC) Advanced Investigator Grant: top EU scientist, 2009

Outstanding Investigator Award from ASGCT in 2014 and from ESGCT in 2015

Bernhard Gentner, M.D.

Bernhard Gentner, M.D.
Founder
Executive Scientific Board Member

Physician Scientist

Group Leader, Translational Stem Cell and Leukemia Research Unit, SR-TIGET, Milan, Italy

Staff Haematologist, Hematology and Bone Marrow Transplantation Unit, San Raffaele Hospital, Milan, Italy

International Training

M.D. studies at the University of Heidelberg, Germany, the MD Anderson Cancer Center and Baylor College of Medicine, Houston, TX, USA

Internal Medicine Training at Erlangen University Hospital, Germany

Hematology Training at San Raffaele Vita-Salute University, Milan, Italy

Author of >30 scientific publications, cumulative IF>386 (avg. IF 11.23), h-index 16, >1.400 citations; Inventor of 2 patents

2012: Abstract Achievement Award by the American Society of Hematology

2011: Young Investigator Award by ESGCT

2009: Excellence in Research Award by ASGTC

Carlo Russo, M.D.

Carlo Russo, M.D.

CMO - Chief Medical Officer

Adverum, Executive VP & CMO

Annapurna, Chief Medical Officer & Head R&D

R&D GSK executive

Head of R&D Rare Disease Unit

Head Development, Alternative Discovery & Development

Head of Development and founding member of GSK R&D Biopharm Unit

Head of Cardiovascular Metabolic Medicine Development Center

General Manager, Founder of GSK internal Biotech Pilot Program, ADP

President & CEO VaxInnate Corporation

Merck Research Laboratories Vaccines – Biologics:

Exec Dir. Head, Department of Global Strategic Regulatory Development for New Vaccines

Faculty and Research Laboratory Head Cornell University Medical College

Columbia University, College of Physicians & Surgeons

Research Fellow, Molecular Immunology, Scripps Research Institute, La Jolla, CA

Founding Member, NIH Geriatrics & Rehabilitative Medicine Study Section

MD and Board Certification in Hematology and Oncology, University of Genoa Medical School, Genoa, Italy

Author of >72 scientific publications